Tillotson, Glenn S[Author] - Search Results

Year	Number of Results
2002	3
2003	2
2004	2
2005	1
2006	3
2007	5
2008	7
2009	3
2010	2
2011	2
2012	2
2013	3
2015	2
2016	5
2017	4
2018	1
2019	3
2020	6
2021	0

1

The burden of community-acquired bacterial pneumonia in the era of antibiotic resistance.

Peyrani P, Mandell L, Torres A, Tillotson GS. Peyrani P, et al. Among authors: tillotson gs. Expert Rev Respir Med. 2019 Feb;13(2):139-152. doi: 10.1080/17476348.2019.1562339. Epub 2018 Dec 30. Expert Rev Respir Med. 2019. PMID: 30596308 Review.

2

Rebuttal From Dr Tillotson.

Tillotson GS. Tillotson GS. Chest. 2016 May;149(5):1133-5. doi: 10.1016/j.chest.2016.01.027. Chest. 2016. PMID: 27157215 No abstract available.

3

A new dawn for the management of influenza?

Tillotson GS. Tillotson GS. Lancet Infect Dis. 2020 Oct;20(10):1112-1114. doi: 10.1016/S1473-3099(20)30459-X. Epub 2020 Jun 8. Lancet Infect Dis. 2020. PMID: 32526194 Free PMC article. No abstract available.

4

Real-World Use of Oritavancin for the Treatment of Osteomyelitis.

Scoble PJ, Reilly J, Tillotson GS. Scoble PJ, et al. Among authors: tillotson gs. Drugs Real World Outcomes. 2020 Jun;7(Suppl 1):46-54. doi: 10.1007/s40801-020-00194-8. Drugs Real World Outcomes. 2020. PMID: 32588387 Free PMC article. Review.

5

Screening for Methicillin resistant Staphylococcus aureus (MRSA) - a valuable antimicrobial stewardship tool?

Tillotson GS, van Hise N. Tillotson GS, et al. Expert Rev Anti Infect Ther. 2020 Dec 24:1-3. doi: 10.1080/14787210.2021.1865800. Online ahead of print. Expert Rev Anti Infect Ther. 2020. PMID: 33331192 No abstract available.

6

Antibiotic resistance: the challenge from an industry perspective.

Tillotson GS. Tillotson GS. Expert Rev Clin Pharmacol. 2009 Mar;2(2):119-23. doi: 10.1586/17512433.2.2.119. Expert Rev Clin Pharmacol. 2009. PMID: 24410641

7

Difficult to Treat: Do We Need a New Definition?

Echols RM, Tillotson GS. Echols RM, et al. Among authors: tillotson gs. Clin Infect Dis. 2019 Oct 15;69(9):1641-1642. doi: 10.1093/cid/ciz184. Clin Infect Dis. 2019. PMID: 30838418 No abstract available.

8

Clostridioides difficile Infection: The Challenge, Tests, and Guidelines.

Lyerly DM, Boone JH, Carman RJ, Tillotson GS. Lyerly DM, et al. Among authors: tillotson gs. ACS Infect Dis. 2020 Nov 13;6(11):2818-2829. doi: 10.1021/acsinfecdis.0c00290. Epub 2020 Oct 2. ACS Infect Dis. 2020. PMID: 32960044

9

Combating resistance while maintaining innovation: the future of antimicrobial stewardship.

Vickers RJ, Bassetti M, Clancy CJ, Garey KW, Greenberg DE, Nguyen MH, Roblin D, Tillotson GS, Wilcox MH. Vickers RJ, et al. Among authors: tillotson gs. Future Microbiol. 2019 Oct;14:1331-1341. doi: 10.2217/fmb-2019-0227. Epub 2019 Sep 17. Future Microbiol. 2019. PMID: 31526186 Free article.

10

New and alternative approaches to tackling antibiotic resistance.

Tillotson GS, Theriault N. Tillotson GS, et al. F1000Prime Rep. 2013 Dec 3;5:51. doi: 10.12703/P5-51. F1000Prime Rep. 2013. PMID: 24381727 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results